Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medi...
February 22 2021 - 8:00AM
Company Announcement
COPENHAGEN, Denmark; February 22, 2021
– Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi,
M.D., Ph.D., has been appointed to the newly created position of
Executive Vice President and Chief Medical Officer, Head of
Experimental Medicines effective March 1, 2021. Dr. Tahi
Ahmadi joined Genmab in 2017 and previously served as Genmab’s
Senior Vice President, Head of Oncology. In this new role, Dr.
Ahmadi will lead research, discovery, regulatory and medical
activities. He joins the Executive Management Team of Chief
Executive Officer Dr. Jan van de Winkel, Chief Development Officer
Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and
Chief Operating Officer Anthony Mancini.
Based in Genmab’s New Jersey, U.S. office, Dr. Ahmadi has been
instrumental in the scale up of the fully integrated R&D
enterprise within Genmab, and he will serve the key role of Chief
Medical Officer as Genmab continues its journey towards a leading
fully integrated biotech innovation powerhouse. Before joining
Genmab, Dr. Ahmadi was head of experimental medicine and early
development oncology at Janssen, where he led the global
development of daratumumab including clinical R&D and medical
affairs strategy. A hematologist/oncologist by training, he holds
an M.D. from the University of Cologne and a Ph.D. in immunology
from the University of Freiburg.
“As we continue to evolve and grow our organization, I am
delighted that Tahi will take on this exciting new role and further
strengthen Genmab’s very strong Executive Management Team. Given
his proven track record of drug development leadership and
innovative thinking, I am confident that Tahi will effectively
drive our R&D teams alongside Judith to deliver on our promise
to create, develop and bring truly differentiated next-generation
antibody medicines to cancer patients,” said Jan van de Winkel,
Ph.D., Chief Executive Officer of Genmab.”
About Genmab Genmab is an international
biotechnology company with a core purpose to improve the lives of
patients with cancer. Founded in 1999, Genmab is the creator of
multiple approved antibody therapeutics that are marketed by its
partners. The company aims to create, develop, and commercialize
differentiated therapies by leveraging next-generation antibody
technologies, expertise in antibody biology, translational research
and data sciences and strategic partnerships. To create novel
therapies, Genmab utilizes its next-generation antibody
technologies, which are the result of its collaborative company
culture and a deep passion for innovation. Genmab’s proprietary
pipeline consists of modified antibody candidates, including
bispecific T-cell engagers and next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates. The company is headquartered in Copenhagen, Denmark
with locations in Utrecht, the Netherlands, Princeton, New Jersey,
U.S. and Tokyo, Japan. For more information, please visit
Genmab.com.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& CommunicationsT: +1 609 524 0065; E: mmp@genmab.com
For Investor Relations: Andrew Carlsen, Senior
Director, Head of Investor RelationsT: +45 3377 9558; E:
acn@genmab.com This Company Announcement contains forward looking
statements. The words “believe”, “expect”, “anticipate”, “intend”
and “plan” and similar expressions identify forward looking
statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual
results or performance to differ materially include, among others,
risks associated with pre-clinical and clinical development of
products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®;
HexaBody®; HexaBody in combination with the HexaBody logo®;
DuoHexaBody®; HexElect®; and UniBody®.
Company Announcement no. 09CVR no. 2102 3884LEI Code
529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024